Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-08-02

FDA Approved: PREVYMIS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Prevymis (letermovir) submitted by Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PREVYMIS (letermovir)

Snippet

SUPPL AP for PREVYMIS (LETERMOVIR)